STC1 Double Nickase Plasmid (h): sc-401423-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- STC1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- STC1 Double Nickase Plasmid (h) and STC1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting STC1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: STC1 Antibody (1A3): sc-293435
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
STC1 Double Nickase Plasmid (h) | sc-401423-NIC | 20 µg | $410.00 | |||
STC1 Double Nickase Plasmid (h2) | sc-401423-NIC-2 | 20 µg | $410.00 |
STC1 (stanniocalcin 1) encodes a secreted glycoprotein hormone implicated in calcium and phosphate homeostasis and broader regulation of cellular stress responses. In human tissues, STC1 is induced by hypoxia and inflammatory cues and has been linked to mitochondrial function, redox balance, and modulation of apoptosis and autophagy programs. STC1 signaling intersects with pathways associated with metabolic adaptation and angiogenic or cytokine-driven microenvironmental remodeling. Altered STC1 expression has been reported across multiple disease contexts, including cancer biology, ischemic injury models, and fibrotic or inflammatory pathologies, making it a useful target for mechanistic studies.
STC1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the STC1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within STC1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt STC1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of STC1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.